Desmodus rotundus salivary plasminogen activator alpha 1

displays strict fibrin specificity; cleared fourfold slower from circulation than t-PA

Also Known As:

salivary plasminogen activator alpha 1, Desmodus rotundus; DSPA alpha 1 protein, Desmodus rotundus; Desmodus salivary plasminogen activator; desmoteplase; salivary plasminogen activator, vampire bat

Networked: 44 relevant articles (11 outcomes, 25 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Al-Rawi, Yasir: 6 articles (09/2012 - 01/2005)
2.	Albers, Gregory W: 5 articles (12/2016 - 05/2006)
3.	Furlan, Anthony J: 5 articles (09/2012 - 05/2006)
4.	Rowley, Howard A: 5 articles (09/2012 - 08/2005)
5.	Warach, Steven: 5 articles (09/2012 - 01/2005)
6.	Bogousslavsky, Julien: 4 articles (03/2022 - 01/2005)
7.	Fiebach, Jochen B: 4 articles (12/2016 - 02/2009)
8.	Kaste, Markku: 4 articles (12/2016 - 01/2005)
9.	Pedraza, Salvador: 4 articles (12/2016 - 02/2009)
10.	Schwamm, Lee H: 4 articles (12/2016 - 02/2009)

Related Diseases

1.	Ischemic Stroke 10/01/2012 - "The results of the Desmoteplase in Acute Ischemic Stroke clinical trial program will show whether patients with major artery occlusions but not extended ischemic brain damage can be safely and effectively treated up to nine-hours after onset." 04/01/2007 - "To date, two published Phase II perfusion imaging-based clinical trials have reported the safety and potential efficacy of desmoteplase in ischemic stroke. " 05/01/2006 - "This study evaluated safety and efficacy of intravenous (IV) desmoteplase in patients with perfusion/diffusion mismatch on MRI 3 to 9 hours after onset of acute ischemic stroke. " 10/01/2012 - "The safety and efficacy of desmoteplase is being studied in the Desmoteplase in Acute Ischemic Stroke clinical trial program. " 03/01/2022 - "However, data from "The desmoteplase in Acute Ischemic Stroke" Trials, DIAS-3 and DIAS-J, suggest that the drug is well tolerated and its safety profile is comparable to placebo. "
2.	Stroke (Strokes) 05/01/2017 - "Well-designed randomized controlled trials with larger patient cohorts and a moderate dose of drugs are needed to further evaluate the true efficacy of desmoteplase in stroke patients. " 09/01/2012 - "Refinement of the magnetic resonance diffusion-perfusion mismatch concept for thrombolytic patient selection: insights from the desmoteplase in acute stroke trials." 02/01/2009 - "The DIAS-2 study did not show a benefit of desmoteplase given 3-9 h after the onset of stroke. " 01/01/2008 - "Although the first trials were promising, the most recent evidence suggests that desmoteplase is not superior to placebo, even in carefully selected patients, in the 3- to 9-hour time window after stroke onset. " 06/01/2015 - "Median time from stroke onset to treatment was 6·9 h (IQR 5·7-8·0) for placebo and 7·0 h (6·0-7·9) for desmoteplase. "
3.	Pathologic Constriction (Stenosis) 06/01/2012 - "In this sample of patients with a mismatch diagnosed, proximal vessel occlusion or severe stenosis was associated with clinically beneficial treatment effects of desmoteplase. " 01/01/2013 - "Desmoteplase is in phase 3 development for the treatment of AIS between 3 and 9 h after onset in AIS patients presenting with occlusion or high-grade stenosis." 06/01/2012 - "In contrast, favorable outcome rates in patients with vessel occlusion/high-grade stenosis (TIMI 0-1) were 18% with placebo versus 36% and 27% with desmoteplase 90 and 125 μg/kg, respectively. " 06/01/2015 - "Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial." 12/01/2016 - "Ischemic stroke patients with occlusion/high-grade stenosis in major cerebral arteries were randomly assigned to intravenous treatment with desmoteplase (90 μg/kg) or placebo. "
4.	Pulmonary Embolism 03/01/2009 - "Desmoteplase in acute massive pulmonary thromboembolism." 03/01/2022 - "Desmoteplase was tested in myocardial infarction and pulmonary embolism and showed promising results versus alteplase. "
5.	Myocardial Infarction 03/01/2022 - "Desmoteplase was tested in myocardial infarction and pulmonary embolism and showed promising results versus alteplase. "

Related Drugs and Biologics

1.	Fibrinolytic Agents (Antithrombotic Agents)
2.	Plasminogen Activators (Plasminogen Activator)
3.	Tissue Plasminogen Activator (Alteplase)
4.	Fibrin
5.	Tenecteplase
6.	Peptide Hydrolases (Proteases)
7.	Tirofiban (Aggrastat)
8.	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)
9.	Plasminogen Activator Inhibitor 1
10.	Factor VIIa (Activated Factor VII)

Related Therapies and Procedures

1.	Therapeutics
2.	Thrombectomy
3.	Thrombolytic Therapy
4.	Time-to-Treatment
5.	Stents